In Development for Cystic Fibrosis

Rare Diseases
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

VP
2 programs
2
VX-770Phase 11 trial
VX-770Phase 11 trial
Active Trials
NCT01153542Completed24Est. Aug 2010
NCT01208285Completed24Est. Dec 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Vertex PharmaceuticalsVX-770
Vertex PharmaceuticalsVX-770

Clinical Trials (2)

Total enrollment: 48 patients across 2 trials

Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects

Start: Sep 2010Est. completion: Dec 201024 patients
Phase 1Completed

Study of VX-770 on Desipramine

Start: Jun 2010Est. completion: Aug 201024 patients
Phase 1Completed

Related Jobs in Rare Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space